Our top pick for
Xencor, Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 166 staff and has a trailing 12-month revenue of around USD$84.4 million.
|Latest market close||USD$40.58|
|52-week range||USD$19.35 - USD$43.9|
|50-day moving average||USD$40.2041|
|200-day moving average||USD$35.495|
|Wall St. target price||USD$49.64|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.607|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||5.73%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Xencor shares trade at around 67x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.5 million.
The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$84.4 million|
|Gross profit TTM||USD$38.1 million|
|Return on assets TTM||-8.77%|
|Return on equity TTM||-14.01%|
|Market capitalisation||USD$2.4 billion|
TTM: trailing 12 months
There are currently 3.9 million Xencor shares held short by investors – that's known as Xencor's "short interest". This figure is 1.3% up from 3.8 million last month.
There are a few different ways that this level of interest in shorting Xencor shares can be evaluated.
Xencor's "short interest ratio" (SIR) is the quantity of Xencor shares currently shorted divided by the average quantity of Xencor shares traded daily (recently around 233067.71273386). Xencor's SIR currently stands at 16.57. In other words for every 100,000 Xencor shares traded daily on the market, roughly 16570 shares are currently held short.
However Xencor's short interest can also be evaluated against the total number of Xencor shares, or, against the total number of tradable Xencor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xencor's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Xencor shares in existence, roughly 70 shares are currently held short) or 0.1421% of the tradable shares (for every 100,000 tradable Xencor shares, roughly 142 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Xencor.
Find out more about how you can short Xencor stock.
We're not expecting Xencor to pay a dividend over the next 12 months.
Over the last 12 months, Xencor's shares have ranged in value from as little as $19.35 up to $43.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.9684. This would suggest that Xencor's shares are less volatile than average (for this exchange).
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; and Catalent Pharma Solutions LLC., as well as a clinical collaboration with MorphoSys AG and Incyte Corporation to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.